Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results
February 29, 2016 8:13 AM ESTPiper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00), following the company's 4Q earnings report. US Contrave royalties of $2.6M, helped OREX end 2015 with $214M of cash, sufficient through profitability based on growing revenues. Orexigen reported 4Q15 revenues of $4.9M, including $2.6M in Contrave... More
UPDATE: RBC Capital Downgrades Orexigen Therapeutics (OREX) to Sector Perform
February 29, 2016 6:52 AM EST(Updated - February 29, 2016 8:24 AM EST)
RBC Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Outperform to Sector Perform with a price target of $1.00 (from $5.00). Analyst Simos Simeonidis sees a tougher road for Contrave/ Mysimba.
"Despite the already significant decline in OREX shares, we are downgrading to Sector Perform on what we view as a bleak outlook for both the US... More
Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
February 26, 2016 7:03 AM ESTOrexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $14.07 million.
According to IMS Health, 185,944 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release... More
